Breaking the Silence on Menstruation and Medicine

Challenging decades of biomedical oversight, MIT has launched the Fairbairn Menstruation Science Fund, a $10 million initiative designed to elevate menstruation research into mainstream biomedical discourse (Jarvis, 2025). For decades, menstruation-related conditions—such as endometriosis, abnormal uterine bleeding, and menstrual-associated autoimmune disorders—have received insufficient scientific attention. This fund aims to change that, transforming how science addresses diseases that affect more than half the global population.

From Lab Bench to Living Avatar

Spearheaded by Professor Linda Griffith at the MIT Center for Gynepathology Research, the initiative brings together microfluidic technology, systems biology, and immunology to develop “living patient avatars.” These advanced models replicate the menstrual environment using human cells and tissues, offering a breakthrough alternative to animal testing. The chip-based platforms support tissue growth complete with vasculature and immune cells, enabling simulation of disease mechanisms and therapeutic responses based on patient-specific biology (Jarvis, 2025).

Rethinking Women’s Health as a Scientific Frontier

More than a research project, this initiative reframes how women’s health is valued in the biomedical ecosystem. The uterus—capable of scarless regeneration and remarkable immune tolerance—offers insights into healing, transplantation, and chronic inflammation. Advancing our understanding of these functions could reshape how we study diseases that affect both sexes but present differently, such as autoimmune disorders or chronic pain syndromes (Jarvis, 2025).

As donor Emily Fairbairn reflects:

“My own experience with both Lyme and endometriosis deepened my conviction that science must better account for how female physiology, genetics, and psychology differ from men’s,” she says. “MIT stands out for treating women’s health not as a niche, but as a frontier. The Institute’s willingness to bridge immunology, neurobiology, bioengineering, and data science — alongside its development of cutting-edge platforms like human chips — offers a rare and necessary seriousness of purpose.” (Jarvis, 2025)

Ethics, Equity, and the Missing Women in Medicines Development

The Fund’s launch also underscores a deeper issue: the underrepresentation of women in clinical research and pharmaceutical leadership. This imbalance not only results in inadequate research on conditions that disproportionately affect women, but also skews drug development strategies, regulatory priorities, and safety assessments.

As emphasized in the Grand Challenges in Pharmaceutical Medicine editorial, ethically grounded medicines development must ensure that research design, data interpretation, and regulatory frameworks are inclusive and representative (Silva et al., 2021). Failing to do so can lead to persistent gaps in health equity, clinical effectiveness, and public trust.

Strengthening Leadership for a New Research Paradigm

This is where Module 7: Leadership in Medicines Development, offered by the GMDP Academy, plays a vital role. While the module does not focus explicitly on gender equity or menstruation science, it supports professionals in building personalized leadership strategies within the complex regulatory and organizational structures of the pharmaceutical ecosystem.

Participants learn to navigate real-world barriers, develop ethical leadership practices, and apply influence across clinical, scientific, and regulatory functions—skills that are essential for advancing inclusive and responsive R&D leadership.

References

Jarvis, M. (2025, July 18). MIT launches a “moonshot for menstruation science”. MIT News. https://news.mit.edu/2025/mit-launches-moonshot-menstruation-for-science-0718

Silva, H., Stonier, P., Chopra, P., et al. (2024). Blended e-learning and certification for medicines development professionals: Results of a 7-year collaboration between King’s College, London and the GMDP Academy, New York. Frontiers in Pharmacology, 15, 1417036. https://doi.org/10.3389/fphar.2024.1417036

Silva, H., Kerpel-Fronius, S., Stonier, P. D., & Dubois, D. J. (2021). Editorial: Grand challenges in pharmaceutical medicine: Competencies and ethics in medicines development. Frontiers in Pharmacology, 12, 666406. https://doi.org/10.3389/fphar.2021.666406

Disclaimers

  • The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
  • Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
  • No official support by any organization(s) has been provided or should be inferred